Published in Toxins (Basel) on July 14, 2010
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect Immun (2013) 0.98
Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol (2016) 0.86
Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.84
Identification of toxemia in patients with Clostridium difficile infection. PLoS One (2015) 0.84
The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol (2014) 0.81
Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region. J Biol Chem (2015) 0.81
Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host. Small GTPases (2014) 0.80
Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist (2013) 0.79
Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS One (2014) 0.79
Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol (2014) 0.79
High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types. BMC Microbiol (2015) 0.78
Study of the frequency of Clostridium difficile tcdA, tcdB, cdtA and cdtB genes in feces of Calves in south west of Iran. Ann Clin Microbiol Antimicrob (2014) 0.78
Host recognition of Clostridium difficile and the innate immune response. Anaerobe (2014) 0.77
Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A. PLoS One (2015) 0.77
What's a SNP between friends: The influence of single nucleotide polymorphisms on virulence and phenotypes of Clostridium difficile strain 630 and derivatives. Virulence (2016) 0.76
Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate. Antimicrob Agents Chemother (2015) 0.76
Clostridium difficile Infection. Clin Transl Gastroenterol (2015) 0.75
Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice. World J Gastroenterol (2014) 0.75
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci (2015) 0.75
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med (2005) 16.59
Clostridium difficile colitis. N Engl J Med (1994) 9.31
CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science (2005) 8.97
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med (2000) 6.24
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med (2006) 4.64
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Clostridium difficile--associated diarrhea. Clin Infect Dis (1998) 4.06
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol (1992) 3.81
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Clostridium difficile infection. Annu Rev Med (1998) 3.63
Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis (2004) 3.42
Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun (2009) 3.36
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest (1988) 3.12
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol (1996) 2.85
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis (1980) 2.59
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Clindamycin-induced enterocolitis in hamsters. J Infect Dis (1978) 2.43
Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.42
Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog (2009) 2.29
Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology (1994) 2.28
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol (2008) 2.25
Epidemiology of Clostridium difficile in infants. J Infect Dis (1982) 2.20
Na+/H+ exchangers of mammalian cells. J Biol Chem (1997) 2.12
Autocatalytic cleavage of Clostridium difficile toxin B. Nature (2007) 2.11
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev (2008) 2.04
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol (2004) 2.00
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant (1998) 1.94
NHE3: a Na+/H+ exchanger isoform of renal brush border. Am J Physiol (1993) 1.93
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology (2003) 1.91
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis (2006) 1.85
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun (2000) 1.75
Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology (2008) 1.74
Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med (1999) 1.74
Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother (1998) 1.72
Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A (1997) 1.70
p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest (2000) 1.68
Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol (1984) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis (2007) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol (2004) 1.60
Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology (2007) 1.60
Neurokinin-1 (NK-1) receptor is required in Clostridium difficile- induced enteritis. J Clin Invest (1998) 1.57
Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun (2002) 1.55
Clostridium difficile-associated diarrhoea. Intern Med J (2007) 1.54
Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol (2001) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun (1983) 1.51
Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864--implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet (1998) 1.49
Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol (1985) 1.47
Structural basis for the function of Clostridium difficile toxin B. J Mol Biol (2005) 1.46
Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem (2003) 1.45
Glucosylation and ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling. Biochemistry (1998) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Update on Clostridium difficile associated disease. Curr Opin Gastroenterol (2007) 1.44
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest (1988) 1.41
Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem (2009) 1.39
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
Toxin A of Clostridium difficile: production, purification and effect in mouse intestine. Acta Pathol Microbiol Immunol Scand B (1983) 1.37
C. difficile toxin A increases intestinal permeability and induces Cl- secretion. Am J Physiol (1990) 1.37
Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut (1980) 1.37
Monocytic cell necrosis is mediated by potassium depletion and caspase-like proteases. Am J Physiol (1999) 1.36
Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A (2006) 1.35
Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology (2007) 1.35
Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control (2007) 1.35
Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A (2005) 1.35
Asymptomatic neonatal colonisation by Clostridium difficile. Arch Dis Child (1984) 1.34
Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol (2000) 1.34
Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb Pathog (1986) 1.34
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione. Gut (2010) 1.73
Enteric glia promote intestinal mucosal healing via activation of focal adhesion kinase and release of proEGF. Am J Physiol Gastrointest Liver Physiol (2011) 1.64
Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc Natl Acad Sci U S A (2004) 1.64
Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci U S A (2004) 1.63
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. Pediatr Res (2003) 1.26
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun (2008) 1.19
Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem (2005) 1.16
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut (2007) 1.05
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother (2003) 1.05
Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol (2005) 1.00
Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood (2003) 0.99
Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog (2009) 0.99
A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol (2005) 0.98
A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93
Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis (2013) 0.90
Development of microbial-human enterocyte interaction: cholera toxin. Pediatr Res (2003) 0.88
Corticotropin-releasing factor regulates TLR4 expression in the colon and protects mice from colitis. Gastroenterology (2010) 0.86
MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85
Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.84
Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer (2004) 0.82
ADAM22 plays an important role in cell adhesion and spreading with the assistance of 14-3-3. Biochem Biophys Res Commun (2005) 0.82
Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. J Biomed Biotechnol (2004) 0.81
Community-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications. J Nurse Pract (2013) 0.80
Clostridial toxins: sensing a target in a hostile gut environment. Gut Microbes (2012) 0.80
Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis. Gut Microbes (2015) 0.80
Involvement of host calpain in the invasion of Cryptosporidium parvum. Microbes Infect (2010) 0.80
Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism. J Toxicol (2011) 0.78
Toxin A-negative, toxin B-positive Clostridium difficile infection diagnosed by polymerase chain reaction. Infect Control Hosp Epidemiol (2011) 0.77
Single domain antibody coated gold nanoparticles as enhancer for Clostridium difficile toxin detection by electrochemical impedance immunosensors. Bioelectrochemistry (2015) 0.76
Interaction of Cryptosporidium parvum with mouse dendritic cells leads to their activation and parasite transportation to mesenteric lymph nodes. Pathog Dis (2013) 0.76
Retracted Retracted: Apoptosis of CT26 colorectal cancer cells induced by Clostridium difficile toxin A stimulates potent anti-tumor immunity. Biochem Biophys Res Commun (2012) 0.75